Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

By M. Sorror, M. Maris, R. Storb, F. Baron, B. Sandmaier, D. Maloney, B. Storer. Blood, 2005

2,847 citations recorded by the source corpus.

We previously reported that the Charlson Comorbidity Index (CCI) was useful for predicting outcomes in patients undergoing allogeneic hematopoietic cell transplantation (HCT). However, the sample size of patients with scores of 1 or more, captured by the CCI, did not exceed 35%. Further, some comorbidities were rarely found among patients who underwent HCT. Therefore, the current study was designed to (1) better define previously identified comorbidities using pretransplant laboratory data, (2) investigate additional HCT-related comorbidities, and (3) establish comorbidity scores that were suited for HCT. Data were collected from 1055 patients, and then randomly divided into training and validation sets. Weights were assigned to individual comorbidities according to their prognostic significance in Cox proportional hazard models. The new index was then validated. The new index proved to be more sensitive than the CCI since it captured 62% of patients with scores more than 0 compared with 12%, respectively. Further, the new index showed better survival prediction than the CCI (likelihood ratio of 23.7 versus 7.1 and c statistics of 0.661 versus 0.561, respectively, P < .001). In conclusion, the new simple index provided valid and reliable scoring of pretransplant comorbidities that predicted nonrelapse mortality and survival. This index will be useful for clinical trials and patient counseling before HCT.

Subfields: Epidemiology, Hematology, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/8f65573dea9a2669dc1301aad79b2b543b4d8110

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

P. Armand
M. Ende
Haesook T. Kim
F. I. Ende
Brent R. Logan
Zhiwei Wang
T. Gooley
E. Alyea

Citations in the corpus

Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. (2009, neutral): “Hewlett et al,13 1995 S8125 1982-1986 28 (16-49) 32 (13-39)b 111 (83-142) No No NR NR”
Reduced mortality after allogeneic hematopoietic cell transplantation (2010, background): “Relapse or progression of a malignant condition 379 (27) 302 (26) 0.”
Hematopoietic stem-cell transplantation. (2006, methodology): “The hematopoietic cell transplantation comorbidity index The hematopoietic cell transplantation comorbidity index (HCT-CI) was developed by investigators at the Fred Hutchinson Cancer Research Center (Seattle, Washington, USA) to allow the risk assessment of patients undergoing transplantation.(57,5”
Therapeutic advances in acute myeloid leukemia. (2011, neutral): “The risk of the SCT can be affected by such factors as the age of the recipient and donor, the cytomegalovirus status of door and host, the parity of a female donor, the degree of matching, and the comorbidities present in the patient, which can be quantitated in a risk score.(27,28) A further compl”
Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. (2014, methodology): “This is already feasible for other variables, such as donor HLA match(1) or comorbidity burden.(2) The Disease Risk Index (DRI) was developed as a tool to assign patients into one of 4 overall survival (OS) risk groups based on disease type and status at the time of transplantation.”